Why Tarsus Pharmaceuticals, Inc.’s (TARS) Stock Is Down 7.71%
As of Wednesday, November 04, Tarsus Pharmaceuticals, Inc.’s TARS share price has dipped by 7.71%, which has investors questioning if this is right time to buy.Rosalio Madrigal
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Rosalio Madrigal
Michael Rose
Cynthia McLaughlin
Michael Rose
| Share Statistics | TARS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,599.8 | $421.5 | 64% |
|
| Shares Out (Mil) | 46.4 | 46.9 | 45% |
|
| Institutional Ownership | 97.2% | 82.0% | 72% |
|
| Float (Mil) | 40.7 | 49.2 | 42% |
|
| Beta | 0.33 | 0.68 | 18% |
|
| Avg Daily Volume (000s) | 703 | 347 | 63% |
|
| Price Change (52-week) |
(5.3%) | 49.3% | 49% |
|
| Growth | TARS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | (19.9%) | (1.3%) | 20% |
|
| EPS (5yr) | 18.1% | 15.1% | 65 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (34.6%) | (15.0%) | 15% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 3 | 4 | |
| Current EPS | ($0.275) | ($15.317) | $0.215 | |
| Month Ago EPS | ($3.207) | ($4.883) | ($0.500) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.044) | ($2.132) | $2.325 | |
| Year/Year Chg | (98.1%) | 863.3% | (288.1%) | |
| Financials | TARS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $682 | $275 | 44% |
|
| Net Income (TTM) (Mil) | ($702) | ($11) | 2% |
|
| EPS (TTM) | ($15.998) | ($0.700) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | $50 | ($7) | 46% |
|
| Net Cash Flow (TTM) (Mil) | $24 | $1 | 64% |
|
| Long-Term Debt (Q1) (Mil) | $89 | $6 | 43% |
|
| Enterprise Value (Q1) (Mil) | $3,109 | $331 | 55% |
|
| Valuation | TARS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 34.60 | 2.08 | 98% |
|
| P/E | na | 20.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | TARS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 83.8% | 69.5% | 91% |
|
| Net Margin | (102.9%) | 3.6% | 8% |
|
| ROA | (135.0%) | (23.8%) | 3% |
|
| ROE | (319.8%) | (24.2%) | 2% |
|
| Liabilities to Assets | 79.4% | 31.6% | 75% |
|
| F-Score | 4 | 3 | 33% |
|
Tarsus Pharmaceuticals, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors